Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.24.69 (botulinum neurotoxin)
 1,901 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Botulinum neurotoxin (BoNT) has become increasingly established in the treatment of neurogenic bladder dysfunctions over the last 12 years. Today it represents an alternative to conservative medical therapy and reduces the indications for broader surgical measures. Since September 2011, BoNT/A is approved for the use in neurogenic bladder disorders. This article therefore summarises the main findings once more, particularly with regard to practical application.The by far most commonly used BoNT subtype is botulinum neurotoxin A (BoNT/A), which has shown the most convincing effects after detrusor injections in the urological field. It unfolds its full effect after about 7 days. Subjective parameters, such as urination frequency, incontinence and quality of life are improved most substantially, which is objectively reflected by the increase in bladder capacity and the reduction of maximum detrusor pressure. Significantly decreasing effectiveness and necessity for repeated injections must be expected after about 9 months. Repeated applications have proven to be effective. Systematic side effects are rare and do not reach dramatic extents. The major urologic side effect, which is not uncommon, is the increase in residual urine, which can lead to urinary retention in patients with spontaneous voiding.
 ...
PMID:[Botulinum toxin for neurogenic bladder dysfunction]. 2226 94